About Aspyrian Therapeutics
Aspyrian Therapeutics is a Healthcare company based in San Diego (United States) founded in 2010, and was acquired by Rakuten in November 2017. Photoimmunotherapy is developed to treat head and neck cancer. Aspyrian Therapeutics has raised $83.01 million across 4 funding rounds from investors including Rakuten and Mickey Mikitani. The company has 36 employees. The company was acqui-hired. Its focus areas include Life Sciences, Immunotherapy, Antibody and Disease-Targeting. Its legal entity is ASPYRIAN THERAPEUTICS INC. Its competitors include Moderna, BeiGene and Incyte; 2 of its 3 listed competitors have raised funding.
Company details
Aspyrian Therapeutics was founded in 2010 in San Diego, United States, as a clinical-stage biotechnology company focused on oncology. Precision targeted oncologic drugs are developed using a proprietary photoimmunotherapy platform for solid tumors. The lead product, RM-1929, an antibody-drug conjugate with a light-activated dye, is currently in phase 1 clinical testing for recurrent head and neck cancer patients. Operations center on advancing this platform for broader tumor applications.
- Headquarters San Diego, United States
- Employees 36
- Stage Acquired
- SectorsHealthcare
- Website aspyriantherapeutics.com
- Social LinkedIn
- Acquired by Rakuten (Nov 2017)
- Legal Name Aspyrian Therapeutics Inc
Funding Insights of Aspyrian Therapeutics
Aspyrian Therapeutics has successfully raised a total of $83.01M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $15.1 million completed in July 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $83.01M
- Total Rounds 4
- Last Round Series B — $15.1M
- First Round $8.46M
(Jan 2015)
- Investors Count 1
All 4 funding rounds of Aspyrian Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2017 | $15.1M | Series B | – | – | |
| Oct 2016 | $55.2M | Series B | – | – | – |
| Jul 2015 | $4.25M | Series A | – | – | – |
| Jan 2015 | $8.46M | Series A | – | – | – |
2 investors in total: 1 institutional and 1 angel.
Investors in Aspyrian Therapeutics
Aspyrian Therapeutics has secured backing from 2 investors, including angel and institutional investors. Prominent investors backing the company include Rakuten and Mickey Mikitani.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Cashback is provided on multi-category products through an app-based platform. | 1997 | rakuten.com | San Francisco, United States | |
MM Mickey Mikitani | Indian angel investor, active in startup ecosystem, focusing on early-stage ventures. | unknown_cf22c84a3f884ec2a |
Investor details for Aspyrian Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Aspyrian Therapeutics
4 dated milestones of Aspyrian Therapeutics across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Aspyrian Therapeutics is founded.
- Funding First funding round of $8.5M.
- Funding Latest funding round, Series B, of $15.1M.
- Exit Acquired by Rakuten.
Competitors of Aspyrian Therapeutics
Aspyrian Therapeutics has 3 listed competitors in our database, 2 of them funded. They include Moderna, BeiGene and Incyte.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| incyte.com | 1991 | Wilmington, United States | 1,387 | Small molecules are developed for cancer and skin disease treatments. |
Detailed competitors of Aspyrian Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Aspyrian Therapeutics (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Aspyrian Therapeutics
Complete news archive for Aspyrian Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Aspyrian Therapeutics
Aspyrian Therapeutics was founded in 2010 and raised its 1st funding round 5 years after it was founded.
Aspyrian Therapeutics is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Aspyrian Therapeutics is a funded company, having raised a total of $83.01M across 4 funding rounds to date. The company's 1st funding round was a Series A of $8.46M, raised on Jan 2015.
Aspyrian Therapeutics has 36 employees.
Aspyrian Therapeutics was founded in 2010 in San Diego, United States, as a clinical-stage biotechnology company focused on oncology. Precision targeted oncologic drugs are developed using a proprietary photoimmunotherapy platform for solid tumors. The lead product, RM-1929, an antibody-drug conjugate with a light-activated dye, is currently in phase 1 clinical testing for recurrent head and neck cancer patients. Operations center on advancing this platform for broader tumor applications.
Aspyrian Therapeutics has 2 investors. Key investors include Rakuten, and Mickey Mikitani.
Aspyrian Therapeutics operates through Aspyrian Therapeutics Inc.
Yes. Aspyrian Therapeutics was acquired by Rakuten in November 2017.